Modular and Mobile changing the way we construct facilities
Biopharmaceuticals are currently produced in fixed facilities that require significant upfront, at-risk capital investment.
Modular and Mobile concepts offer an opportunity to shift this paradigm away from these large, fixed assets to networks of smaller, standardized manufacturing facilities that can be built in less than half the time and in a way that defers cost until there is greater certainty about market demand and the probability of success. Amongst the other benefits of this approach to facility design is that this standardization of the manufacturing platform provides the opportunity to accelerate the delivery of therapies to the market whilst the responsiveness of the supply chains can be improved and the regulatory review for new products and for adding additional capacity can be simplified.
This is 1 of 8 roadmap documents, to download others click on the ‘First Edition Documents’ menu